Additionally, miR-43a acts as an inhibitor of PD-L-1, reduces the expression of PD-L-1 mRNA, exhibits an anti-tumor effect, and mimics MRX34 enters a clinical trial to explore its antitumor effect [188]. Here, CD274 is linked to neoplasm.